Arbutus Biopharma Corporation is a publicly traded Canadian (NASDAQ: ABUS) biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| ABUS | Arbutus Biopharma Corp | 2026-04-02 18:56:07 | 4.45 | -0.03 | -0.67 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABUS | 0001447028 | Arbutus Biopharma Corp | US03879J1007 | 25490064CESONAUIAS23 | 980597776 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | A1 | 701 VETERANS CIRCLE | WARMINSTER | PA | 18974 | UNITED STATES | US | 604-419-3200 | 701 VETERANS CIRCLE, WARMINSTER, PA, 18974 | 701 VETERANS CIRCLE, WARMINSTER, PA, 18974 | TEKMIRA PHARMACEUTICALS CORP | Biotechnology | 2007 | — | — | http://arbutusbio.com/ | 472,133,611 | 192,531,225 | 195,478,068 | Arbutus Biopharma Corporation is a publicly traded Canadian (NASDAQ: ABUS) biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection. | 2026-04-02 17:30:07 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 472,133,611 | 17,733,998 | 3.9027 | 195,478,068 | 3,997,880 | 2.0879 |
| 2024 | 454,399,613 | 166,270,802 | 57.7071 | 191,480,188 | 11,987,989 | 6.6788 |
| 2023 | 288,128,811 | -2,295,867 | -0.7905 | 179,492,199 | 16,921,210 | 10.4085 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Karen Sims | Chief Medical Officer | 2024 | 490,000 | 0 | 242,400 | 196,000 | 17,250 | 1,697,375 |
| Michael J. Sofia | Chief Scientific Officer | 2024 | 512,000 | 0 | 262,800 | 204,800 | 25,636 | 1,820,054 |
| Michael Mcelhaugh | Chief Executive Officer, President | 2024 | 642,500 | 0 | 297,120 | 231,750 | 17,250 | 2,110,083 |
| David C. Hastings | Chief Financial Officer | 2024 | 502,000 | 0 | 270,000 | 200,800 | 15,522 | 1,825,846 |
| William H. Collier | Chief Executive Officer, President | 2023 | 637,100 | 0 | 627,850 | 0 | 223,558 | 3,385,984 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 19 |
| 2024 | 44 |
| 2023 | 73 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 14,083,000 | 6,171,000 | 18,141,000 |
| Cost Of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | 25,241,000 | 54,037,000 | 73,700,000 |
| General And Administrative Expenses | 15,893,000 | 22,108,000 | 22,475,000 |
| Operating Expenses | 52,243,000 | 82,490,000 | 96,244,000 |
| Operating Income | -38,160,000 | -76,319,000 | -78,103,000 |
| Net Income | -33,501,000 | -69,920,000 | -72,849,000 |
| Earnings Per Share Basic | -0.17 | -0.38 | -0.44 |
| Earnings Per Share Diluted | -0.17 | -0.38 | -0.44 |
| Weighted Average Shares Outstanding Basic | 191,599,600 | 185,608,874 | 165,960,379 |
| Weighted Average Shares Outstanding Diluted | 191,599,600 | 185,608,874 | 165,960,379 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 18,008,000 | 36,330,000 | 26,285,000 |
| Marketable Securities Current | 73,463,000 | 86,293,000 | 99,718,000 |
| Accounts Receivable | 1,447,000 | 2,409,000 | 1,776,000 |
| Inventories | — | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 94,456,000 | 127,316,000 | 132,027,000 |
| Marketable Securities Non Current | 0 | 0 | 6,284,000 |
| Property Plant And Equipment | 32,000 | 3,309,000 | 4,674,000 |
| Other Assets Non Current | 130,000 | 34,000 | 0 |
| Total Assets Non Current | 162,000 | 4,391,000 | 12,374,000 |
| Total Assets | 94,618,000 | 131,707,000 | 144,401,000 |
| Accounts Payable | 1,173,000 | 2,316,000 | 3,223,000 |
| Deferred Revenue | 0 | 7,571,000 | 11,791,000 |
| Short Term Debt | — | — | — |
| Other Liabilities Current | — | — | — |
| Total Liabilities Current | 6,006,000 | 15,618,000 | 22,487,000 |
| Long Term Debt | 0 | 0 | 0 |
| Other Liabilities Non Current | — | — | — |
| Total Liabilities Non Current | 12,036,000 | 18,723,000 | 15,896,000 |
| Total Liabilities | 18,042,000 | 34,341,000 | 38,383,000 |
| Common Stock | 1,421,429,000 | 1,410,025,000 | 1,349,821,000 |
| Retained Earnings | -1,380,073,000 | -1,346,572,000 | -1,276,652,000 |
| Accumulated Other Comprehensive Income | -48,098,000 | -48,135,000 | -48,421,000 |
| Total Shareholders Equity | 76,576,000 | 97,366,000 | 106,018,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 363,000 | 1,380,000 | 1,404,000 |
| Share Based Compensation Expense | 6,953,000 | 8,986,000 | 9,301,000 |
| Other Non Cash Income Expense | 674,000 | 0 | 20,000 |
| Change In Accounts Receivable | -1,375,000 | 633,000 | 424,000 |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | -2,105,000 | -2,707,000 | -5,758,000 |
| Change In Other Liabilities | -557,000 | -430,000 | -444,000 |
| Cash From Operating Activities | -39,637,000 | -64,850,000 | -85,936,000 |
| Purchases Of Marketable Securities | 140,061,000 | 141,509,000 | 80,509,000 |
| Sales Of Marketable Securities | 155,277,000 | 164,639,000 | 132,270,000 |
| Acquisition Of Property Plant And Equipment | 0 | 182,000 | 1,008,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | 15,580,000 | 22,948,000 | 50,773,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 181,000 | 396,000 | 535,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 5,721,000 | 51,996,000 | 30,647,000 |
| Change In Cash | -18,322,000 | 10,045,000 | -4,491,000 |
| Cash At End Of Period | 18,008,000 | 36,330,000 | 26,285,000 |
| Income Taxes Paid | 4,400,000 | 4,400,000 | 4,400,000 |
| Interest Paid | — | — | 459,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -0.17 | -0.38 | -0.44 |
| Price To Earnings Ratio | -28.2941 | -8.6053 | -5.6818 |
| Earnings Growth Rate | -55.2632 | -13.6364 | -4.3478 |
| Price Earnings To Growth Ratio | 0.512 | 0.6311 | 1.3068 |
| Book Value Per Share | 0.3997 | 0.5246 | 0.6388 |
| Price To Book Ratio | 12.035 | 6.2336 | 3.9135 |
| Ebitda | -28,641,000 | -64,003,000 | -66,586,000 |
| Enterprise Value | 903,586,076 | 570,611,017.98 | 388,615,947.5 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 0 | 0 | 0 |
| Capital Expenditures | -2,914,000 | 15,000 | 1,008,000 |
| Free Cash Flow | -36,723,000 | -64,865,000 | -86,944,000 |
| Return On Equity | -0.4375 | -0.7181 | -0.6871 |
| One Year Beta | 0.8658 | 0.7999 | 1.0183 |
| Three Year Beta | 0.8812 | 1.0966 | 1.0305 |
| Five Year Beta | 0.9608 | 0.9448 | 1.0053 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Androski Lindsay | Director, President and CEO | 2026-02-02 | 28,000 | A | 28,000 |
| Androski Lindsay | Director, President and CEO | 2026-02-02 | 71,700 | A | 71,700 |
| Nguyen Tuan | Chief Financial Officer | 2026-02-02 | 73,500 | A | 73,500 |
| Nguyen Tuan | Chief Financial Officer | 2026-02-02 | 188,400 | A | 188,400 |
| Sawhney Roger | Director | 2025-08-04 | 157,600 | A | 157,600 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| GOLDMAN SACHS GROUP INC | 2025-12-31 | 3,552,570 | 738,580 | 4.81 |
| Rockefeller Capital Management L.P. | 2025-12-31 | 303,030 | 63,000 | 4.81 |
| Caitong International Asset Management Co., Ltd | 2025-12-31 | 15,075 | 3,134 | 4.8101 |
| Invesco Ltd. | 2025-12-31 | 1,189,292 | 247,254 | 4.81 |
| ADAR1 Capital Management, LLC | 2025-12-31 | 26,046,674 | 5,415,109 | 4.81 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Direxion Shares ETF Trust | 2026-01-31 | Direxion Daily S&P Biotech Bull 3X ETF | LABU | 77,640 | 320,653.2 | 0.0556 |
| Global X Funds | 2026-01-31 | Global X Russell 2000 ETF | RSSL | 68,482 | 282,830.66 | 0.0204 |
| Pacer Funds Trust | 2026-01-31 | Pacer WealthShield ETF | PWS | 1,522 | 6,285.86 | 0.02 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 2026-01-31 | Invesco RAFI US 1500 Small-Mid ETF | PRFZ | 133,540 | 551,520.2 | 0.0206 |
| ProFunds | 2026-01-31 | SMALL-CAP PROFUND SERVICE CLASS | SLPSX | 159 | 656.67 | 0.0087 |